{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122298","form_type":"8-K","ticker":"MYO","cik":"0001369290","company_name":"MYOMO, INC.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.271792+00:00","generated_at":"2026-05-30T04:24:20.543946+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myomo Q3 revenue record $9.2M (+81% YoY); FY guidance raised to $30-31M","bullets":["Record Q3 product revenue $9.2M, +83% YoY; net loss $1.0M ($0.03/sh) vs $2.0M loss year ago.","Gross margin 75.4%, +670 bps; backlog record 316 units (+71%); 225 MyoPro orders (+44%).","Raised FY2024 revenue guidance to $30-31M from prior $28-30M; expects Q4 rev $9.5-10.5M.","Cash $7.0M; expects approaching operating cash flow breakeven in Q4.","Cost per pipeline add $1,618, down 25%; 1,263 patients in pipeline (+21%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122298","json":"https://secwatch.observer/filing/0000950170-24-122298.json","markdown":"https://secwatch.observer/filing/0000950170-24-122298.md","text":"https://secwatch.observer/filing/0000950170-24-122298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369290/000095017024122298/0000950170-24-122298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369290/000095017024122298/myo-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:24:20.543946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}